Creative Planning Makes New $110,000 Investment in Exagen Inc. (NASDAQ:XGN)

Creative Planning bought a new position in shares of Exagen Inc. (NASDAQ:XGN) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 35,500 shares of the company’s stock, valued at approximately $110,000. Creative Planning owned 0.20% of Exagen as of its most recent filing with the Securities and Exchange Commission.

Separately, Renaissance Technologies LLC boosted its position in shares of Exagen by 93.3% during the second quarter. Renaissance Technologies LLC now owns 94,234 shares of the company’s stock valued at $172,000 after purchasing an additional 45,476 shares in the last quarter. Hedge funds and other institutional investors own 75.25% of the company’s stock.

Exagen Price Performance

XGN opened at $2.79 on Wednesday. The company has a current ratio of 4.32, a quick ratio of 4.32 and a debt-to-equity ratio of 1.13. The company has a market cap of $48.51 million, a price-to-earnings ratio of -2.88 and a beta of 1.35. The stock has a fifty day simple moving average of $2.84 and a two-hundred day simple moving average of $2.36. Exagen Inc. has a 12-month low of $1.30 and a 12-month high of $3.71.

Exagen Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).